The Drug-Induced Respiratory Disease Website and App

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.d Acute eosinophilic pneumonia (AEP)

I. Interstitial/parenchymal lung disease

I.k Exogenous lipoid pneumonia (subacute, acute)

I. Interstitial/parenchymal lung disease

I.n ILD with a granulomatous component

I. Interstitial/parenchymal lung disease

I.t A mass or masses

I. Interstitial/parenchymal lung disease

I.u Pneumoconiosis (silicosis, talcosis...)

II. Pulmonary edema - Acute lung injury - ARDS

II.a Pulmonary edema, noncardiogenic (NCPE)

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

IV. Airway involvement

IV.b Severe or catastrophic bronchospasm or asthma attack (can be fatal)

IV. Airway involvement

IV.ae Cough syncope

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.c Upper airway obstruction other than angioedema or hematoma

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.i Thermal (burns, frostbite), chemical or caustic injury on the face, mouth, tongue, pharynx or upper airway

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.aj Nasal, palatal and/or pharyngeal pathology

VI. Pleural and/or pericardial involvement

VI.f Pneumothorax

VI. Pleural and/or pericardial involvement

VI.r Empyema

VI. Pleural and/or pericardial involvement

VI.ac Pneumothorax, bilateral

VII. Pulmonary vasculopathy

VII.b Pulmonary arterial hypertension

VII. Pulmonary vasculopathy

VII.c Pulmonary veno-occlusive disease

VII. Pulmonary vasculopathy

VII.g Foreign body pulmonary vasculopathy (Excipient lung disease)

VII. Pulmonary vasculopathy

VII.i Acute pulmonary hypertension

VII. Pulmonary vasculopathy

VII.j Mercury pulmonary embolism

VII. Pulmonary vasculopathy

VII.q Septic pulmonary embolism

VII. Pulmonary vasculopathy

VII.r Pulmonary artery aneurysm(s)

VIII. Mediastinal involvement

VIII.h Pneumomediastinum

VIII. Mediastinal involvement

VIII.i Mediastinitis

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.a Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.s Botulism (foodborne-, wound-)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.ah Acute myelopathy (can cause ARF)

X. Systemic/Distant conditions, syndromes and reactions

X.o Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)

X. Systemic/Distant conditions, syndromes and reactions

X.w Multiple organ dysfunction/failure (MODS/MOF)

X. Systemic/Distant conditions, syndromes and reactions

X.ae Anti-GBM antibody disease (Goodpasture-like or flare of preexisting GS)

X. Systemic/Distant conditions, syndromes and reactions

X.bc Foreign body (talc, cornstarch) retinopathy

XI. Miscellaneous

XI.b Chest pain (acute or subacute), lone or prominent

XI. Miscellaneous

XI.h Aspiration, aspiration pneumonia (w/wo demonstrable pharyngeal dysmotility)

XI. Miscellaneous

XI.k Pulmonary emphysema - Lung cysts or bullae

XI. Miscellaneous

XI.o Death following exposure or poisoning

XII. Cardiovascular involvement / toxicity

XII.h Coronary artery disease (acute) - Myocardial ischemia/infarction

XII. Cardiovascular involvement / toxicity

XII.j Endocarditis (infective)

XII. Cardiovascular involvement / toxicity

XII.x Hypertrophic cardiomyopathy

XVI. Imaging

XVI.d Imaging: Alveolar opacities or haze with a batwing or butterfly distribution

XVI. Imaging

XVI.u Imaging: A miliary pattern (diffuse random micronodules)

XVI. Imaging

XVI.v Imaging: Centrilobular micronodules (can be diffuse)

XVI. Imaging

XVI.ac Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

XVI. Imaging

XVI.ad Imaging: Lung cysts or bullae (see also XVI ah/bf)

XVI. Imaging

XVI.ag Imaging: A pattern similar to pneumoconiotic progressive massive fibrosis (PMF)

XVI. Imaging

XVI.ak Imaging: A 'tree-in-bud' pattern

XVII. Distinctive patterns - 'Eye-catchers'

XVII.t Eye catcher: Purpuric/Ecchymotic/Cyanotic lesions of the earlobes and/or nose

XVII. Distinctive patterns - 'Eye-catchers'

XVII.u Eye catcher: Talc retinopathy

XVII. Distinctive patterns - 'Eye-catchers'

XVII.x Eye catcher: A batwing pattern on imaging

XIX. Pathology

XIX.j Path: Micronodular organizing pneumonia/BOOP

XIX. Pathology

XIX.ab Path: Foreign body deposits/granulomatous reaction

XIX. Pathology

XIX.ac Path: Pneumoconiosis (silicosis, talcosis, talcoma)

XIX. Pathology

XIX.an Path: Foreign body embolism, microangiopathy, vasculopathy

XIX. Pathology

XIX.ax Path: Pulmonary hypertension incl. angiomatoid vasculopathy

XX. Infections & related conditions

XX.a Respiratory tract infection incl. pneumonia

XX. Infections & related conditions

XX.b Opportunistic pulmonary/systemic infections

XX. Infections & related conditions

XX.g Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

XX. Infections & related conditions

XX.p Lung abscess/abscesses (see also VIr)

XX. Infections & related conditions

XX.s Sternoclavicular septic arthritis

XX. Infections & related conditions

XX.t Epidural abscess

XX. Infections & related conditions

XX.ak Osteomyelitis (notably of thoracic bones)

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.d Acute eosinophilic pneumonia (AEP)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.f Acute fibrinous organizing pneumonia (AFOP)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.i Subclinical pulmonary infiltrates/ILD

I. Interstitial/parenchymal lung disease

I.l Lung nodule or nodules

I. Interstitial/parenchymal lung disease

I.m Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

I. Interstitial/parenchymal lung disease

I.t A mass or masses

I. Interstitial/parenchymal lung disease

I.v Relapsing or migrating pneumonitis/pneumonia (see also Id)

I. Interstitial/parenchymal lung disease

I.x Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome)

I. Interstitial/parenchymal lung disease

I.aa An area or areas of consolidation

I. Interstitial/parenchymal lung disease

I.ab Delayed ILD, -pneumonitis, -fibrosis

I. Interstitial/parenchymal lung disease

I.ap Pulmonary infiltrates

I. Interstitial/parenchymal lung disease

I.au Amiodarone pulmonary toxicity - Amiodarone lung

I. Interstitial/parenchymal lung disease

I.ay Chronic pneumonitis

I. Interstitial/parenchymal lung disease

I.az Unilateral interstitial lung disease

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

II. Pulmonary edema - Acute lung injury - ARDS

II.m Postoperative ARDS

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.c Hemoptysis

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

IV. Airway involvement

IV.k Airway pigmentation (black, bluish, petechial)

IV. Airway involvement

IV.ab Cough (lone)

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.a Angioedema (may cause UAO, asphyxia and death)

VI. Pleural and/or pericardial involvement

VI.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

VI. Pleural and/or pericardial involvement

VI.c Pleural thickening - Fibrothorax

VI. Pleural and/or pericardial involvement

VI.d Pleural/pericardial effusion, ANA positive (DI lupus)

VI. Pleural and/or pericardial involvement

VI.u The apical cap

VII. Pulmonary vasculopathy

VII.a Pulmonary embolism - Venous thrombosis/thromboembolism

VII. Pulmonary vasculopathy

VII.i Acute pulmonary hypertension

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.a Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.d Respiratory failure from ventilatory depression (due to neuromuscular blockade/paralysis)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.ai Acute respiratory failure (hypoxemia, acidosis) from myxedema (-coma)

X. Systemic/Distant conditions, syndromes and reactions

X.d Lupus - Lupus syndrome (see also Vd)

X. Systemic/Distant conditions, syndromes and reactions

X.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

X. Systemic/Distant conditions, syndromes and reactions

X.s Systemic inflammatory response

XI. Miscellaneous

XI.c Pleuritic chest pain

XI. Miscellaneous

XI.g Bluish, pseudocyanotic skin discoloration

XII. Cardiovascular involvement / toxicity

XII.a Left or biventricular dysfunction/failure

XII. Cardiovascular involvement / toxicity

XII.c Pericardial effusion (w/wo tamponade)

XII. Cardiovascular involvement / toxicity

XII.f Takotsubo (stress) cardiomyopathy

XII. Cardiovascular involvement / toxicity

XII.n Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)

XII. Cardiovascular involvement / toxicity

XII.o Cardiovascular collapse - Cardiogenic shock - Hypotension

XII. Cardiovascular involvement / toxicity

XII.q QTc prolongation

XII. Cardiovascular involvement / toxicity

XII.v Torsades de pointe

XII. Cardiovascular involvement / toxicity

XII.ah Coronary vasospasm - Vasospastic angina

XII. Cardiovascular involvement / toxicity

XII.aw Heart failure (thyrotoxicosis-, thyroid storm-mediated)

XV. Pulmonary physiology - PFTs

XV.g Platypnea-orthodeoxia

XVI. Imaging

XVI.b Imaging: Ground-glass opacities (GGO) / shadowing

XVI. Imaging

XVI.i Imaging: An area or areas of involvement with a recognizable anatomic distribution

XVI. Imaging

XVI.j Imaging: Wandering (migratory) pulmonary opacities

XVI. Imaging

XVI.n Imaging: Intralobular septal thickening - Crazy paving

XVI. Imaging

XVI.s Imaging: An area or areas of involvement with high attenuation numbers or metallic density

XVI. Imaging

XVI.w Imaging: Lung nodule or nodules

XVI. Imaging

XVI.x Imaging: Waxing and waning nodules

XVI. Imaging

XVI.ab Imaging: Nodules, mass or masses with a central area of low attenuation (see also under XVIaa)

XVI. Imaging

XVI.ac Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

XVI. Imaging

XVI.ba Imaging: Asymmetrical, predominantly unilateral involvement

XVI. Imaging

XVI.bb Imaging: Solitary pulmonary nodule

XVI. Imaging

XVI.bn Imaging: Atelectasis (a combination of increased density and volume loss. Typically lobar)

XVI. Imaging

XVI.bt Imaging: A pattern consistent with pleuroparenchymal fibroelastosis

XVI. Imaging

XVI.bv Imaging: A subsolid lung nodule or nodules

XVI. Imaging

XVI.cb Imaging: Disseminated patchy pulmonary opacities

XVII. Distinctive patterns - 'Eye-catchers'

XVII.b Eye catcher: Electron-dense area or areas of consolidation on unenhanced chest CT

XVII. Distinctive patterns - 'Eye-catchers'

XVII.j Eye-catcher: Avid lung uptake on 18F-PET-CT

XVII. Distinctive patterns - 'Eye-catchers'

XVII.k Eye-catcher: An electron-dense liver on unenhanced CT

XVII. Distinctive patterns - 'Eye-catchers'

XVII.p Eye-catcher: An electron-dense ('white') thyroid

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.a BAL: An excess proportion of lymphocytes

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.b BAL: An excess proportion of neutrophils

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.c BAL: An excess proportion of eosinophils

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.e BAL: Stainable iron in macrophages

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.f BAL: Foamy macrophages

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.m BAL: A normal cell differential

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.p BAL: Lamellar bodies in AM on EM

XIX. Pathology

XIX.a Path: NSIP-cellular pattern (see also Ia, Ib)

XIX. Pathology

XIX.b Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)

XIX. Pathology

XIX.c Path: Acute eosinophilic pneumonia pattern (see also under XVIb)

XIX. Pathology

XIX.d Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

XIX. Pathology

XIX.e Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)

XIX. Pathology

XIX.k Path: Desquamative interstitial pneumonia (DIP-pattern)

XIX. Pathology

XIX.o Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

XIX. Pathology

XIX.q Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign)

XIX. Pathology

XIX.r Path: Alveolar hemorrhage (see also IIIa)

XIX. Pathology

XIX.v Path: NSIP-fibrotic pattern

XIX. Pathology

XIX.w Path: Pulmonary fibrosis (UIP-pattern)

XIX. Pathology

XIX.aa Path: Endogenous lipoid pneumonia (phospholipidosis)

XIX. Pathology

XIX.ae Path: Foamy inclusions in alveolar macrophages and/or in other lung cells

XIX. Pathology

XIX.ag Path: Histiocytic proliferation

XIX. Pathology

XIX.aj Path: Lymphoid hyperplasia (including nodular- or a lymphocytic interstitial pneumonia pattern)

XIX. Pathology

XIX.ak Path: Smudged geographic necrosis

XIX. Pathology

XIX.bm Path: Pleuritis, pleural fibrosis

XX. Infections & related conditions

XX.e Pneumocystis jiroveci pneumonia

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.c Hemoptysis

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.g Bleeding/hemorrhage from/around preexisting lung tumor (Localized AH)

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.h Major/massive hemoptysis

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.k Epistaxis

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.m Perforation of the nasal septum

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.s Tracheal/large airway necrosis, chondronecrosis, perforation

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.ab Airway (e.g. tracheoesophageal) fistula

VI. Pleural and/or pericardial involvement

VI.f Pneumothorax

VII. Pulmonary vasculopathy

VII.a Pulmonary embolism - Venous thrombosis/thromboembolism

VII. Pulmonary vasculopathy

VII.b Pulmonary arterial hypertension

X. Systemic/Distant conditions, syndromes and reactions

X.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

X. Systemic/Distant conditions, syndromes and reactions

X.u Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive

XI. Miscellaneous

XI.t Cavitation/necrosis of lung tumor or metastases

XII. Cardiovascular involvement / toxicity

XII.a Left or biventricular dysfunction/failure

XII. Cardiovascular involvement / toxicity

XII.f Takotsubo (stress) cardiomyopathy

XII. Cardiovascular involvement / toxicity

XII.g Cardiomyopathy (acute, subacute, chronic)

XII. Cardiovascular involvement / toxicity

XII.h Coronary artery disease (acute) - Myocardial ischemia/infarction

XII. Cardiovascular involvement / toxicity

XII.ak Cardiotoxicity

XII. Cardiovascular involvement / toxicity

XII.al Systemic arterial thrombosis

XII. Cardiovascular involvement / toxicity

XII.av Aortitis

XIII. Esophageal involvement

XIII.f Esophageal pleural fistula

XVI. Imaging

XVI.ac Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

XVI. Imaging

XVI.ad Imaging: Lung cysts or bullae (see also XVI ah/bf)

XVI. Imaging

XVI.bh Imaging: Tumoral cavitation

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.f Acute fibrinous organizing pneumonia (AFOP)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.l Lung nodule or nodules

I. Interstitial/parenchymal lung disease

I.m Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

I. Interstitial/parenchymal lung disease

I.q Fatal pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.w Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence

I. Interstitial/parenchymal lung disease

I.x Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome)

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

II. Pulmonary edema - Acute lung injury - ARDS

II.u Acute respiratory failure (e.g. from ARDS, ILD, PIE, OP, pulmonary edema or bronchospasm) requiring ECMO

VI. Pleural and/or pericardial involvement

VI.f Pneumothorax

VI. Pleural and/or pericardial involvement

VI.p Pleuroparenchymal fibroelastosis (PPFE)

VI. Pleural and/or pericardial involvement

VI.aa Pneumothorax (associated or secondary to drug-induced ILD)

VII. Pulmonary vasculopathy

VII.c Pulmonary veno-occlusive disease

VII. Pulmonary vasculopathy

VII.f Hemolytic and uremic syndrome (HUS). See also under Xaf

VIII. Mediastinal involvement

VIII.e Granulomatous mediastinal lymphadenopathy

VIII. Mediastinal involvement

VIII.h Pneumomediastinum

XI. Miscellaneous

XI.b Chest pain (acute or subacute), lone or prominent

XI. Miscellaneous

XI.c Pleuritic chest pain

XVI. Imaging

XVI.a Imaging: Diffuse haze

XVI. Imaging

XVI.b Imaging: Ground-glass opacities (GGO) / shadowing

XVI. Imaging

XVI.e Imaging: Pulmonary opacities with a subpleural distribution

XVI. Imaging

XVI.k Imaging: An area or areas of consolidation

XVI. Imaging

XVI.w Imaging: Lung nodule or nodules

XVI. Imaging

XVI.ac Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

XVI. Imaging

XVI.ad Imaging: Lung cysts or bullae (see also XVI ah/bf)

XVI. Imaging

XVI.bp Imaging: An area or areas of avid tracer uptake in the lung/chest on 18F-PET scan

XVII. Distinctive patterns - 'Eye-catchers'

XVII.j Eye-catcher: Avid lung uptake on 18F-PET-CT

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.b BAL: An excess proportion of neutrophils

XIX. Pathology

XIX.a Path: NSIP-cellular pattern (see also Ia, Ib)

XIX. Pathology

XIX.b Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)

XIX. Pathology

XIX.d Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

XIX. Pathology

XIX.e Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)

XIX. Pathology

XIX.g Path: Pulmonary necrotizing granuloma or granulomas

XIX. Pathology

XIX.i Path: Focal organizing pneumonia

XIX. Pathology

XIX.o Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

XIX. Pathology

XIX.q Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign)

XIX. Pathology

XIX.u Path: Interstitial pulmonary edema

XIX. Pathology

XIX.v Path: NSIP-fibrotic pattern

XIX. Pathology

XIX.w Path: Pulmonary fibrosis (UIP-pattern)

XIX. Pathology

XIX.x Path: Pulmonary fibrosis (not otherwise specified or unclassifiable)

XXVI. Veterinary medicine

XXVI.a Veterinary: Pneumonitis - Interstitial lung disease

XXVI. Veterinary medicine

XXVI.d Veterinary: Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.d Acute eosinophilic pneumonia (AEP)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.l Lung nodule or nodules

I. Interstitial/parenchymal lung disease

I.m Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

II. Pulmonary edema - Acute lung injury - ARDS

II.a Pulmonary edema, noncardiogenic (NCPE)

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

VI. Pleural and/or pericardial involvement

VI.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

VI. Pleural and/or pericardial involvement

VI.d Pleural/pericardial effusion, ANA positive (DI lupus)

VIII. Mediastinal involvement

VIII.a Lymphadenopathy (intrathoracic)

VIII. Mediastinal involvement

VIII.b Lymphadenopathy with reactive changes

X. Systemic/Distant conditions, syndromes and reactions

X.a DRES syndrome - DRESS-like reaction

X. Systemic/Distant conditions, syndromes and reactions

X.d Lupus - Lupus syndrome (see also Vd)

X. Systemic/Distant conditions, syndromes and reactions

X.o Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)

XII. Cardiovascular involvement / toxicity

XII.a Left or biventricular dysfunction/failure

XII. Cardiovascular involvement / toxicity

XII.c Pericardial effusion (w/wo tamponade)

XII. Cardiovascular involvement / toxicity

XII.d Myocarditis (can be fulminant)

XII. Cardiovascular involvement / toxicity

XII.n Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)

XII. Cardiovascular involvement / toxicity

XII.t Heart block (bundle branch- or AV-)

XVI. Imaging

XVI.ac Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

XIX. Pathology

XIX.a Path: NSIP-cellular pattern (see also Ia, Ib)

XIX. Pathology

XIX.b Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)

XIX. Pathology

XIX.d Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

XIX. Pathology

XIX.f Path: ILD with a granulomatous component (see also Im)

XXI. Neoplastic conditions

XXI.b Lymphoproliferative disease (pulmonary, endobronchial, endothoracic)

VI. Pleural and/or pericardial involvement

VI.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

VII. Pulmonary vasculopathy

VII.g Foreign body pulmonary vasculopathy (Excipient lung disease)

X. Systemic/Distant conditions, syndromes and reactions

X.s Systemic inflammatory response

X. Systemic/Distant conditions, syndromes and reactions

X.u Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive

XVI. Imaging

XVI.w Imaging: Lung nodule or nodules

XVI. Imaging

XVI.ac Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

XVI. Imaging

XVI.ap Imaging: Pleural effusion

XIX. Pathology

XIX.ab Path: Foreign body deposits/granulomatous reaction

XIX. Pathology

XIX.an Path: Foreign body embolism, microangiopathy, vasculopathy

XIX. Pathology

XIX.bk Path: Hydrophilic polymer emboli

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.k Exogenous lipoid pneumonia (subacute, acute)

I. Interstitial/parenchymal lung disease

I.ag Chemical (toxic) pneumonitis

II. Pulmonary edema - Acute lung injury - ARDS

II.a Pulmonary edema, noncardiogenic (NCPE)

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.b Pneumorenal syndrome (w/wo ANCAs)

IV. Airway involvement

IV.h Reactive airway dysfunction syndrome (RADS)

IV. Airway involvement

IV.x Obliterative bronchiolitis (a pattern consistent with) (see also IVn, XVx)

IV. Airway involvement

IV.ag Obstructive airway dysfunction (see also IVc, XVx)

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.c Upper airway obstruction other than angioedema or hematoma

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.f Vocal cord dysfunction, adduction, closure, injury

VI. Pleural and/or pericardial involvement

VI.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

X. Systemic/Distant conditions, syndromes and reactions

X.o Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)

X. Systemic/Distant conditions, syndromes and reactions

X.w Multiple organ dysfunction/failure (MODS/MOF)

X. Systemic/Distant conditions, syndromes and reactions

X.ae Anti-GBM antibody disease (Goodpasture-like or flare of preexisting GS)

XI. Miscellaneous

XI.p Sniffing death - Death from inhalation of compound

XII. Cardiovascular involvement / toxicity

XII.u Cardiac- cardiorespiratory/pulmonary arrest

XIV. Hemoglobinopathies - Abnormal hemoglobin states (acquired)

XIV.a Methemoglobinemia

XIV. Hemoglobinopathies - Abnormal hemoglobin states (acquired)

XIV.c Sulfhemoglobinemia

XVI. Imaging

XVI.ac Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

XIX. Pathology

XIX.al Path: Acute/subacute bronchiolitis (see also IVc, IVi)

XX. Infections & related conditions

XX.p Lung abscess/abscesses (see also VIr)

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.f Acute fibrinous organizing pneumonia (AFOP)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.i Subclinical pulmonary infiltrates/ILD

I. Interstitial/parenchymal lung disease

I.l Lung nodule or nodules

I. Interstitial/parenchymal lung disease

I.m Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

I. Interstitial/parenchymal lung disease

I.n ILD with a granulomatous component

I. Interstitial/parenchymal lung disease

I.o Pulmonary alveolar proteinosis (PAP)

I. Interstitial/parenchymal lung disease

I.w Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence

I. Interstitial/parenchymal lung disease

I.x Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome)

I. Interstitial/parenchymal lung disease

I.y Pleuroparenchymal fibroelastosis (PPFE)

I. Interstitial/parenchymal lung disease

I.z Progression, acceleration or exacerbation of preexisting ILD/fibrosis

I. Interstitial/parenchymal lung disease

I.ab Delayed ILD, -pneumonitis, -fibrosis

I. Interstitial/parenchymal lung disease

I.ae Radiation recall pneumonitis

I. Interstitial/parenchymal lung disease

I.av The chemotherapy lung

II. Pulmonary edema - Acute lung injury - ARDS

II.a Pulmonary edema, noncardiogenic (NCPE)

II. Pulmonary edema - Acute lung injury - ARDS

II.b Pulmonary edema, cardiogenic

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

II. Pulmonary edema - Acute lung injury - ARDS

II.f ARDS and the hemolytic-uremic syndrome (HUS)

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

IV. Airway involvement

IV.j Bronchiectasis

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.a Angioedema (may cause UAO, asphyxia and death)

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.g Vocal cord paresis/paralysis

VI. Pleural and/or pericardial involvement

VI.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

VI. Pleural and/or pericardial involvement

VI.f Pneumothorax

VI. Pleural and/or pericardial involvement

VI.ac Pneumothorax, bilateral

VII. Pulmonary vasculopathy

VII.b Pulmonary arterial hypertension

VII. Pulmonary vasculopathy

VII.c Pulmonary veno-occlusive disease

VII. Pulmonary vasculopathy

VII.f Hemolytic and uremic syndrome (HUS). See also under Xaf

VIII. Mediastinal involvement

VIII.a Lymphadenopathy (intrathoracic)

VIII. Mediastinal involvement

VIII.h Pneumomediastinum

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.f Hiccup

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.j Phrenic nerve injury - Hemi- or bilateral diaphragmatic paralysis

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.o Pneumorachis

X. Systemic/Distant conditions, syndromes and reactions

X.c Capillary leak syndrome (CLS)

X. Systemic/Distant conditions, syndromes and reactions

X.d Lupus - Lupus syndrome (see also Vd)

X. Systemic/Distant conditions, syndromes and reactions

X.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

X. Systemic/Distant conditions, syndromes and reactions

X.i Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

X. Systemic/Distant conditions, syndromes and reactions

X.m Sarcoid-like granulomatosis (endo-/extrathoracic)

X. Systemic/Distant conditions, syndromes and reactions

X.p Tumor lysis syndrome (TLS)

XI. Miscellaneous

XI.b Chest pain (acute or subacute), lone or prominent

XI. Miscellaneous

XI.l Neutropenia, agranulocytosis (w/wo infection/sepsis)

XI. Miscellaneous

XI.t Cavitation/necrosis of lung tumor or metastases

XII. Cardiovascular involvement / toxicity

XII.a Left or biventricular dysfunction/failure

XII. Cardiovascular involvement / toxicity

XII.b Valvular heart disease and/or dysfunction

XII. Cardiovascular involvement / toxicity

XII.c Pericardial effusion (w/wo tamponade)

XII. Cardiovascular involvement / toxicity

XII.f Takotsubo (stress) cardiomyopathy

XII. Cardiovascular involvement / toxicity

XII.g Cardiomyopathy (acute, subacute, chronic)

XII. Cardiovascular involvement / toxicity

XII.h Coronary artery disease (acute) - Myocardial ischemia/infarction

XII. Cardiovascular involvement / toxicity

XII.m Atrial fibrillation

XII. Cardiovascular involvement / toxicity

XII.n Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)

XII. Cardiovascular involvement / toxicity

XII.t Heart block (bundle branch- or AV-)

XII. Cardiovascular involvement / toxicity

XII.ak Cardiotoxicity

XVI. Imaging

XVI.ac Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

XVI. Imaging

XVI.ad Imaging: Lung cysts or bullae (see also XVI ah/bf)

XVI. Imaging

XVI.bh Imaging: Tumoral cavitation

XVI. Imaging

XVI.bp Imaging: An area or areas of avid tracer uptake in the lung/chest on 18F-PET scan

XVI. Imaging

XVI.by Imaging: Air or an air crescent around lung tumor or metastase(s)

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.g BAL: Atypical epithelial cells (at times poetically named

XIX. Pathology

XIX.d Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

XIX. Pathology

XIX.e Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)

XIX. Pathology

XIX.o Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

XIX. Pathology

XIX.q Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign)

XIX. Pathology

XIX.x Path: Pulmonary fibrosis (not otherwise specified or unclassifiable)

XIX. Pathology

XIX.ba Path: Thrombosis in pulmonary arterioles/venules

XIX. Pathology

XIX.bd Path: Pulmonary veno-occlusive disease (PVOD)

XIX. Pathology

XIX.bx Path: Granulomatous lymphadenopathy

XX. Infections & related conditions

XX.b Opportunistic pulmonary/systemic infections

XX. Infections & related conditions

XX.c Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma)

XX. Infections & related conditions

XX.e Pneumocystis jiroveci pneumonia

XX. Infections & related conditions

XX.g Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

XX. Infections & related conditions

XX.j Mucormycosis (pulmonary, tracheobronchial or systemic)

XX. Infections & related conditions

XX.r Fungal infection (pulmonary/extrapulmonary)

XX. Infections & related conditions

XX.ae Reactivation of a prior pulmonary infection (TB, melioidosis)

XXI. Neoplastic conditions

XXI.a Lung cancer

XXI. Neoplastic conditions

XXI.b Lymphoproliferative disease (pulmonary, endobronchial, endothoracic)

XXI. Neoplastic conditions

XXI.d Malignant mesothelioma (pleural, pericardial)

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.k Exogenous lipoid pneumonia (subacute, acute)

I. Interstitial/parenchymal lung disease

I.aa An area or areas of consolidation

I. Interstitial/parenchymal lung disease

I.af Hydrocarbon pneumonitis

I. Interstitial/parenchymal lung disease

I.ag Chemical (toxic) pneumonitis

I. Interstitial/parenchymal lung disease

I.ah Fire-eater's lung/pneumonitis

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.c Hemoptysis

IV. Airway involvement

IV.j Bronchiectasis

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.i Thermal (burns, frostbite), chemical or caustic injury on the face, mouth, tongue, pharynx or upper airway

VI. Pleural and/or pericardial involvement

VI.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

XI. Miscellaneous

XI.b Chest pain (acute or subacute), lone or prominent

XI. Miscellaneous

XI.p Sniffing death - Death from inhalation of compound

XIV. Hemoglobinopathies - Abnormal hemoglobin states (acquired)

XIV.a Methemoglobinemia

XVI. Imaging

XVI.b Imaging: Ground-glass opacities (GGO) / shadowing

XVI. Imaging

XVI.f Imaging: Bibasilar opacities/shadowing

XVI. Imaging

XVI.k Imaging: An area or areas of consolidation

XVI. Imaging

XVI.ac Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

XVI. Imaging

XVI.ai Imaging: Pneumatoceles (see also XVIaf)

XVI. Imaging

XVI.aj Imaging: Pneumatocele or pneumatoceles

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.a BAL: An excess proportion of lymphocytes

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.h BAL: Exogenous (oil red O-stainable) lipids in BAL macrophages

XIX. Pathology

XIX.cd Path: Fire eater's lung

XX. Infections & related conditions

XX.p Lung abscess/abscesses (see also VIr)

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.d Acute eosinophilic pneumonia (AEP)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.f Acute fibrinous organizing pneumonia (AFOP)

I. Interstitial/parenchymal lung disease

I.i Subclinical pulmonary infiltrates/ILD

I. Interstitial/parenchymal lung disease

I.ae Radiation recall pneumonitis

I. Interstitial/parenchymal lung disease

I.ak Shrinking lung syndrome

II. Pulmonary edema - Acute lung injury - ARDS

II.b Pulmonary edema, cardiogenic

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.g Bleeding/hemorrhage from/around preexisting lung tumor (Localized AH)

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.j Anti-GBM-related pneumorenal syndrome and DAH (Goodpasture) or flare of

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.m Coagulopathy

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

IV. Airway involvement

IV.d Exacerbation or deterioration of preexisting COPD

IV. Airway involvement

IV.t Eosinophilic airway disease (asthma, bronchitis, bronchiolitis)

IV. Airway involvement

IV.w Bronchiolitis (a clinical-imaging pattern suggestive of)

IV. Airway involvement

IV.x Obliterative bronchiolitis (a pattern consistent with) (see also IVn, XVx)

IV. Airway involvement

IV.af Sputum production - Bonchorrhea - ‘Bronchitis’

IV. Airway involvement

IV.ag Obstructive airway dysfunction (see also IVc, XVx)

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.g Vocal cord paresis/paralysis

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.au Rhinosinusitis

VI. Pleural and/or pericardial involvement

VI.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

VI. Pleural and/or pericardial involvement

VI.m Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative)

VII. Pulmonary vasculopathy

VII.b Pulmonary arterial hypertension

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.a Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.d Respiratory failure from ventilatory depression (due to neuromuscular blockade/paralysis)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.h Dyspnea, unexplained otherwise

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.r Myasthenia gravis - Myasthenic-like syndrome

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.y A flare or relapse of preexisting myasthenia gravis

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.ab Guillain-Barré (or GB-like) syndrome (w/wo ARF)

X. Systemic/Distant conditions, syndromes and reactions

X.a DRES syndrome - DRESS-like reaction

X. Systemic/Distant conditions, syndromes and reactions

X.d Lupus - Lupus syndrome (see also Vd)

X. Systemic/Distant conditions, syndromes and reactions

X.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

X. Systemic/Distant conditions, syndromes and reactions

X.i Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

X. Systemic/Distant conditions, syndromes and reactions

X.l Myopathy-Myositis-Polymyositis (see also under Xba)

X. Systemic/Distant conditions, syndromes and reactions

X.m Sarcoid-like granulomatosis (endo-/extrathoracic)

X. Systemic/Distant conditions, syndromes and reactions

X.o Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)

X. Systemic/Distant conditions, syndromes and reactions

X.p Tumor lysis syndrome (TLS)

X. Systemic/Distant conditions, syndromes and reactions

X.u Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive

X. Systemic/Distant conditions, syndromes and reactions

X.w Multiple organ dysfunction/failure (MODS/MOF)

X. Systemic/Distant conditions, syndromes and reactions

X.ae Anti-GBM antibody disease (Goodpasture-like or flare of preexisting GS)

X. Systemic/Distant conditions, syndromes and reactions

X.az Polymyalgia rheumatica

XI. Miscellaneous

XI.as Deterioration of graft function in SOT recipients

XI. Miscellaneous

XI.bi Esophageal necrosis

XII. Cardiovascular involvement / toxicity

XII.c Pericardial effusion (w/wo tamponade)

XII. Cardiovascular involvement / toxicity

XII.d Myocarditis (can be fulminant)

XII. Cardiovascular involvement / toxicity

XII.h Coronary artery disease (acute) - Myocardial ischemia/infarction

XII. Cardiovascular involvement / toxicity

XII.o Cardiovascular collapse - Cardiogenic shock - Hypotension

XII. Cardiovascular involvement / toxicity

XII.t Heart block (bundle branch- or AV-)

XII. Cardiovascular involvement / toxicity

XII.ak Cardiotoxicity

XII. Cardiovascular involvement / toxicity

XII.az Necrotizing myocarditis (w/o evidence for CAD)

XIII. Esophageal involvement

XIII.c Esophageal stenosis/stricture

XIII. Esophageal involvement

XIII.d Esophageal toxicity

XVI. Imaging

XVI.i Imaging: An area or areas of involvement with a recognizable anatomic distribution

XVI. Imaging

XVI.v Imaging: Centrilobular micronodules (can be diffuse)

XVI. Imaging

XVI.w Imaging: Lung nodule or nodules

XVI. Imaging

XVI.ac Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

XVI. Imaging

XVI.ad Imaging: Lung cysts or bullae (see also XVI ah/bf)

XVI. Imaging

XVI.ak Imaging: A 'tree-in-bud' pattern

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.a BAL: An excess proportion of lymphocytes

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.b BAL: An excess proportion of neutrophils

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.c BAL: An excess proportion of eosinophils

XIX. Pathology

XIX.d Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

XIX. Pathology

XIX.e Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)

XIX. Pathology

XIX.r Path: Alveolar hemorrhage (see also IIIa)

XIX. Pathology

XIX.al Path: Acute/subacute bronchiolitis (see also IVc, IVi)

XIX. Pathology

XIX.am Path: Peribronchiolar granulomas

XIX. Pathology

XIX.au Path: Airway inflammation

XX. Infections & related conditions

XX.a Respiratory tract infection incl. pneumonia

XX. Infections & related conditions

XX.c Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma)

XX. Infections & related conditions

XX.g Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

XX. Infections & related conditions

XX.ai Bordetella bronchiseptica pulmonary infection

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.k Exogenous lipoid pneumonia (subacute, acute)

I. Interstitial/parenchymal lung disease

I.l Lung nodule or nodules

I. Interstitial/parenchymal lung disease

I.t A mass or masses

I. Interstitial/parenchymal lung disease

I.aa An area or areas of consolidation

I. Interstitial/parenchymal lung disease

I.aq Paraffinoma - Lipidoma (ELP in the form of a nodule or mass)

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.c Hemoptysis

IV. Airway involvement

IV.r Plugs/casts in the airways

VIII. Mediastinal involvement

VIII.p Lipid-laden mediastinal lymphadenopathy

X. Systemic/Distant conditions, syndromes and reactions

X.e Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)

XVI. Imaging

XVI.a Imaging: Diffuse haze

XVI. Imaging

XVI.b Imaging: Ground-glass opacities (GGO) / shadowing

XVI. Imaging

XVI.f Imaging: Bibasilar opacities/shadowing

XVI. Imaging

XVI.i Imaging: An area or areas of involvement with a recognizable anatomic distribution

XVI. Imaging

XVI.k Imaging: An area or areas of consolidation

XVI. Imaging

XVI.n Imaging: Intralobular septal thickening - Crazy paving

XVI. Imaging

XVI.r Imaging: An area or areas of involvement with low attenuation numbers

XVI. Imaging

XVI.w Imaging: Lung nodule or nodules

XVI. Imaging

XVI.aa Imaging: A large nodule or a mass

XVI. Imaging

XVI.ac Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

XVI. Imaging

XVI.bb Imaging: Solitary pulmonary nodule

XVI. Imaging

XVI.be Imaging: Intrathoracic lymph node enlargement

XVII. Distinctive patterns - 'Eye-catchers'

XVII.r Eye catcher: A milky, cloudy or lumpy BAL fluid

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.a BAL: An excess proportion of lymphocytes

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.h BAL: Exogenous (oil red O-stainable) lipids in BAL macrophages

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.j BAL: Free exogenous lipids in supernatant

XIX. Pathology

XIX.f Path: ILD with a granulomatous component (see also Im)

XIX. Pathology

XIX.v Path: NSIP-fibrotic pattern

XIX. Pathology

XIX.z Path: Exogenous lipoid pneumonia

XIX. Pathology

XIX.ab Path: Foreign body deposits/granulomatous reaction

XIX. Pathology

XIX.de Path: Exogenous lipid-laden lymphadenopathy

XX. Infections & related conditions

XX.h Nontuberculous pulmonary mycobacterial infection/superinfection

XXI. Neoplastic conditions

XXI.a Lung cancer

XXVI. Veterinary medicine

XXVI.c Veterinary: Exogenous lipoid pneumonia

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.w Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence

I. Interstitial/parenchymal lung disease

I.z Progression, acceleration or exacerbation of preexisting ILD/fibrosis

I. Interstitial/parenchymal lung disease

I.ac Radiation-induced lung injury (RILI)

I. Interstitial/parenchymal lung disease

I.ad Acute radiation pneumonitis

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.c Upper airway obstruction other than angioedema or hematoma

VI. Pleural and/or pericardial involvement

VI.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

VI. Pleural and/or pericardial involvement

VI.h Chylothorax

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.h Dyspnea, unexplained otherwise

XI. Miscellaneous

XI.t Cavitation/necrosis of lung tumor or metastases

XII. Cardiovascular involvement / toxicity

XII.l Constrictive pericarditis - Pericardial thickening

XVI. Imaging

XVI.ac Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

XVI. Imaging

XVI.bp Imaging: An area or areas of avid tracer uptake in the lung/chest on 18F-PET scan

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.a BAL: An excess proportion of lymphocytes

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.c BAL: An excess proportion of eosinophils

XIX. Pathology

XIX.a Path: NSIP-cellular pattern (see also Ia, Ib)

XIX. Pathology

XIX.b Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)

XIX. Pathology

XIX.d Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

XIX. Pathology

XIX.e Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)

XIX. Pathology

XIX.o Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

XIX. Pathology

XIX.q Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign)

XIX. Pathology

XIX.v Path: NSIP-fibrotic pattern

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.i Subclinical pulmonary infiltrates/ILD

I. Interstitial/parenchymal lung disease

I.p Focal/localized area of pneumonitis/fibrosis

I. Interstitial/parenchymal lung disease

I.w Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence

I. Interstitial/parenchymal lung disease

I.y Pleuroparenchymal fibroelastosis (PPFE)

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.c Hemoptysis

IV. Airway involvement

IV.j Bronchiectasis

IV. Airway involvement

IV.ai Bronchial stenosis/stricture

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.c Upper airway obstruction other than angioedema or hematoma

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.d Laryngeal disorder-Laryngeal nerve palsy (dysphonia, hoarseness)

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.g Vocal cord paresis/paralysis

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.s Tracheal/large airway necrosis, chondronecrosis, perforation

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.aa Pseudomembranous tracheitis/tracheobronchitis

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.ab Airway (e.g. tracheoesophageal) fistula

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.ac Large airway necrosis

VI. Pleural and/or pericardial involvement

VI.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

VI. Pleural and/or pericardial involvement

VI.b Eosinophilic pleural effusion

VI. Pleural and/or pericardial involvement

VI.c Pleural thickening - Fibrothorax

VI. Pleural and/or pericardial involvement

VI.f Pneumothorax

VI. Pleural and/or pericardial involvement

VI.h Chylothorax

VI. Pleural and/or pericardial involvement

VI.l Malignant pleural mesothelioma

VI. Pleural and/or pericardial involvement

VI.m Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative)

VI. Pleural and/or pericardial involvement

VI.u The apical cap

VII. Pulmonary vasculopathy

VII.c Pulmonary veno-occlusive disease

VII. Pulmonary vasculopathy

VII.r Pulmonary artery aneurysm(s)

VII. Pulmonary vasculopathy

VII.aa Pulmonary artery stenosis

VIII. Mediastinal involvement

VIII.d Fibrosing mediastinitis

VIII. Mediastinal involvement

VIII.i Mediastinitis

VIII. Mediastinal involvement

VIII.j Compression of mediastinal structures/organs

VIII. Mediastinal involvement

VIII.l Calcification of mediastinal lymph nodes

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.a Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.aj Paraspinal muscle myositis/myopathy/neuromyopathy +- the dropped head syndrome

XI. Miscellaneous

XI.h Aspiration, aspiration pneumonia (w/wo demonstrable pharyngeal dysmotility)

XI. Miscellaneous

XI.m Chest deformity: platythorax

XI. Miscellaneous

XI.s Rib fracture

XI. Miscellaneous

XI.ad Vertebral compression fracture

XI. Miscellaneous

XI.bc Aorto-esophageal fistula

XI. Miscellaneous

XI.bn Dropped-head syndrome

XII. Cardiovascular involvement / toxicity

XII.a Left or biventricular dysfunction/failure

XII. Cardiovascular involvement / toxicity

XII.b Valvular heart disease and/or dysfunction

XII. Cardiovascular involvement / toxicity

XII.g Cardiomyopathy (acute, subacute, chronic)

XII. Cardiovascular involvement / toxicity

XII.h Coronary artery disease (acute) - Myocardial ischemia/infarction

XII. Cardiovascular involvement / toxicity

XII.l Constrictive pericarditis - Pericardial thickening

XII. Cardiovascular involvement / toxicity

XII.p Coronary artery disease (subacute, chronic)

XII. Cardiovascular involvement / toxicity

XII.t Heart block (bundle branch- or AV-)

XII. Cardiovascular involvement / toxicity

XII.af Effusive-constrictive pericarditis

XII. Cardiovascular involvement / toxicity

XII.am Late left ventricular dysfunction/failure

XII. Cardiovascular involvement / toxicity

XII.ap Pericardial calcification

XII. Cardiovascular involvement / toxicity

XII.bf Coarctation of the aorta (acquired)

XII. Cardiovascular involvement / toxicity

XII.bx Aortoesophageal fistula

XIII. Esophageal involvement

XIII.b Esophageal pathology (erosion, ulcer, tear, rupture, fistula)

XIII. Esophageal involvement

XIII.c Esophageal stenosis/stricture

XIII. Esophageal involvement

XIII.d Esophageal toxicity

XVI. Imaging

XVI.ac Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

XVI. Imaging

XVI.bm Imaging: Hyperlucent lung

XVI. Imaging

XVI.bn Imaging: Atelectasis (a combination of increased density and volume loss. Typically lobar)

XVI. Imaging

XVI.bp Imaging: An area or areas of avid tracer uptake in the lung/chest on 18F-PET scan

XIX. Pathology

XIX.o Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

XIX. Pathology

XIX.x Path: Pulmonary fibrosis (not otherwise specified or unclassifiable)

XXI. Neoplastic conditions

XXI.a Lung cancer

XXI. Neoplastic conditions

XXI.d Malignant mesothelioma (pleural, pericardial)

XXI. Neoplastic conditions

XXI.e Breast cancer

XXI. Neoplastic conditions

XXI.j Pulmonary synovial sarcoma

XXI. Neoplastic conditions

XXI.l Chondrosarcoma

XXI. Neoplastic conditions

XXI.m Tumor of the heart